Aram Zabeti
University of Cincinnati
Quality of lifeMacrophage migration inhibitory factorProteomeInternal medicineEndocrinologyGenotypePathologyMagnetic resonance imagingDermatologyCardiologyAllelePhysical therapyMcDonald criteriaCohort studyNeuroimmunologyImmunologyHaptoglobinPlaceboOxidative stressAspergillosisArea postremaPars compactaRespiratory failureIbudilastInfliximabTransverse myelitisPleocytosisHuman brainHydrocephalusCorpus callosumCoronary artery diseaseNeurosarcoidosisMyelinDiscontinuationOcrelizumabHemoglobinSpasticityDiseaseResearch designDuane syndromeCerebrospinal fluidParkinson's diseaseCongenital disorderElectrocardiographyWeaknessImmunosuppressionMultiple sclerosisVoriconazoleExtramuralSpinal cordSubstantia nigraPathogenesisNeuromyelitis opticaLesionAtrophyWhite matterSarcoidosisPopulationProgressive multiple sclerosisHemoglobin bindingCyclic nucleotide phosphodiesterasesDisease progressionCognitive declineTemporal cortexCoronavirus disease 2019 (COVID-19)Infusion timeIn patientSafety profileProteomicsRisk factorObesityCentral nervous systemClinical trialMidbrainComputational biologyMedicineScopusBiologyPharmacology
10Publications
4H-index
203Citations
Publications 14
Newest
#1Mary Rensel (Cleveland Clinic)H-Index: 14
#2Aram Zabeti (UC: University of Cincinnati)H-Index: 4
Last. Eliezer KatzH-Index: 7
view all 7 authors...
Background:Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive for aquaporin-4 (AQP4)–immunoglobulin (Ig) G were demonstrated in the 2...
Source
#2Aram Zabeti (UC: University of Cincinnati)H-Index: 4
view all 4 authors...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by recurrent optic neuritis and transverse myelitis often resulting in severe disability. Anti-aquaporin-4-immunoglobulin (Ig) G is a pathogenic product of CD19-positive plasma cells found in most, but not all, individuals with NMOSD and is associated with immune-mediated neurologic injury. Inebilizumab, an afucosylated humanized IgG1 κ, anti-CD19 monoclonal antibody, may target pathogenic CD19-expressing B...
Source
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 8
#2bagherieh S (IUMS: Isfahan University of Medical Sciences)H-Index: 1
Last. Aram Zabeti (UC: University of Cincinnati)H-Index: 4
view all 9 authors...
Background: We conducted this systematic review to identify factors associated with coronavirus disease (COVID-19) susceptibility and outcomes among people with multiple sclerosis (MS). Methods: Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature including reference list and conference abstracts were searched from December 1, 2019, through April 12, 2021. We included cross-sectional, case-control, and cohort studies that reported risk factors of contracting COVID-1...
Source
#1Robert A. BermelH-Index: 26
#2Emmanuelle Waubant (UCSF: University of California, San Francisco)H-Index: 72
Last. Aram ZabetiH-Index: 4
view all 11 authors...
The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing-remitting multiple sclerosis who had a suboptimal response to previous disease-modifying treatment. The objective of the present study was to assess the safety of shorter OCR infusions in a substudy of CHORDS. After completing four doses of OCR per initial US prescribing recommendations in the main study, participants in the substudy (N = 129) received a fifth dose over a 2-h duration (vs. 3.5 h). Infusion-related reactions ...
Source
#1Carson Van Sanford (UC: University of Cincinnati)H-Index: 2
#2Ahmed Z. Obeidat (MCW: Medical College of Wisconsin)H-Index: 5
Last. Aram Zabeti (UC: University of Cincinnati)H-Index: 4
view all 4 authors...
AbstractIntroduction: CNS involvement in sarcoidosis is seen in 5–10% of cases. Long term treatment involves steroids and other immunomodulatory agents, including infliximab. Chronic immunosuppression can result in increased patient susceptibility to opportunistic infections. We present a case of fatal aspergillosis in a patient with neurosarcoidosis treated with infliximab. Case report: A 55-year-old woman with neurosarcoidosis on infliximab (started 4 months prior) and dexamethasone, presented...
Source
Abstract Background There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and tol...
Source
#1Daniel OntanedaH-Index: 23
#2Emma C TallantyreH-Index: 18
Last. Nikos EvangelouH-Index: 38
view all 35 authors...
#1Carson Van Sanford (UC: University of Cincinnati)H-Index: 2
#2Ahmed Z. Obeidat (UC: University of Cincinnati)H-Index: 5
Last. Aram Zabeti (UC: University of Cincinnati)H-Index: 4
view all 3 authors...
Objective: To highlight a case of ring-enhancing lesions in a patient with definite-neurosarcoidosis on infliximab. Background: Central nervous system (CNS) involvement in sarcoidosis is seen in 5–10% of cases. Long term treatment involves steroids and steroid-sparing immunomodulatory agents. Chronic immunomodulation can result in increased patient susceptibility to opportunistic infections. Ring-enhancing lesions on brain MRI are nonspecific findings and could be attributed to infectious (inclu...
Source
Abstract Background Primary and secondary progressive multiple sclerosis (MS), collectively called progressive multiple sclerosis (PMS), is characterized by gradual progression of disability. The current anti-inflammatory treatments for MS have little or no efficacy in PMS in the absence of obvious active inflammation. Optimal biomarkers for phase II PMS trials is unknown. Ibudilast is an inhibitor of macrophage migration inhibitor factor and phosphodiesterases-4 and − 10 and exhibits possible n...
Source
Close Researchers
Ahmed Z. Obeidat
H-index : 5
Medical College of Wisconsin
Pavle Repovic
H-index : 8
University of Washington
Robert A. Bermel
H-index : 26
Cleveland Clinic
Merit Cudkowicz
H-index : 80
Harvard University
Andrew D. Goodman
H-index : 55
University of Rochester Medical Center
Khurram Bashir
H-index : 16
University of Alabama at Birmingham
Sharon G. Lynch
H-index : 36
University of Kansas
Silvia Delgado
H-index : 11
University of Miami
Trevis Gleason
H-index : 2
Cleveland Clinic
Vijayshree Yadav
H-index : 25
Oregon Health & Science University
Jeffrey D. Long
H-index : 59
University of Iowa
Brenda Thornell
H-index : 5
Harvard University
Christopher Severson
H-index : 9
Brigham and Women's Hospital
Robert T. Naismith
H-index : 31
Washington University in St. Louis
Dixie Ecklund
H-index : 11
University of Iowa
Daniel Ontaneda
H-index : 23
Cleveland Clinic
Robin Conwit
H-index : 32
National Institutes of Health
Jon W. Yankey
H-index : 13
University of Iowa
Shlomo Shinnar
H-index : 99
Albert Einstein College of Medicine
Burk Jubelt
H-index : 18
State University of New York Upstate Medical University
Christopher S Coffey
H-index : 16
Montreal Neurological Institute and Hospital
Claire S Riley
H-index : 13
Columbia University Medical Center
Carson Van Sanford
H-index : 2
University of Cincinnati
Michael K. Racke
H-index : 75
Quest Diagnostics
Neil Lava
H-index : 5
Emory University
Valerie Suski
H-index : 8
University of Pittsburgh
Maxine Koepp
H-index : 2
University of Iowa
Harold L. Moses
H-index : 125
Vanderbilt University
Bruce A. Cohen
H-index : 71
Northwestern University
Michelle McGovern
H-index : 6
Harvard University
Sneha Natarajan
H-index : 3
Cleveland Clinic
Myla D. Goldman
H-index : 24
Virginia Commonwealth University
Jai Perumal
H-index : 12
Cornell University
Barbara Giesser
H-index : 25
Oregon Health & Science University
Eric C. Klawiter
H-index : 24
Harvard University
Robert J. Fox
H-index : 55
Cleveland Clinic
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.